Key facts
- VeraDermics (NYS: MANE)’s last known valuation is $596.3M (Feb 2026).
- It has raised $518.6M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($150.0M) in Oct 2025.
- Notable investors include Viking Global Investors, Connecticut Innovations, The Invus Group, Osage University Partners, Marshall Wace — 26 tracked in total.
- 4 institutional filers report fund marks on VeraDermics (NYS: MANE) across 8 filings.
- Status: Publicly Held.
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for VeraDermics (NYS: MANE)
Funding rounds
1 roundsAbout VeraDermics (NYS: MANE)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2019
- Employees
- 19
- Website
- veradermics.com/
- Ownership
- Publicly Held
VeraDermics (NYS: MANE) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VeraDermics (NYS: MANE) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 8 fair-value marks on VeraDermics (NYS: MANE) between Feb 2026 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.